
Advocacy during COVID-19: what can we do in Africa?
The COVID-19 pandemic has significantly affected the bleeding disorders community, and many countries have seen their governments shift their focus
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The global bleeding disorders community reached a major milestone in 2025, as the World Health Organization updated both its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to align with modern international guidelines for hemophilia and von Willebrand disease. Led by the World Federation of Hemophilia (WFH), this achievement reflects two years of coordinated global advocacy, scientific collaboration, and direct engagement with the WHO. These updates will help improve equitable access to safer and more effective therapies for people with bleeding disorders worldwide.
In this video, watch a WFH expert panel discussion held in November 2025, where global stakeholders reflect on the significance of these landmark changes and what they mean for patients, clinicians, and health systems worldwide.
The panel is chaired by David Page, Consultant, Safety and Supply of Coagulation Products, Canadian Hemophilia Society and WFH Coagulation Product Safety, Supply and Access (CPSSA) Committee Member, includes the following speakers (in order of their seating in the video, left to right): Alain Baumann, CEO, WFH; Glenn Pierce, MD, PhD, WFH Vice President, Medical; Salome Mekhuzla, Director, Global Development, WFH; Radek Kaczmarek, Chair of the Coagulation Product Safety, Supply and Access (CPSSA) Committee, WFH; Mark W. Skinner, Board Member, WFH USA; Maria Elisa Mancuso, MD; Brian O’Mahony, Chief Executive, Irish Haemophilia Society; and Cesar Garrido, President, WFH.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

The COVID-19 pandemic has significantly affected the bleeding disorders community, and many countries have seen their governments shift their focus

Listen to this 1-hour webinar that took place on 27 November 2020, chaired by Baiba Zimele (WFH lay member). Presenters

Listen to this 75-minute workshop that took place on 26th November 2020, moderated by Clive Smith (UK), WFH lay member,

This 1-hour webinar on the WFH Development Grant Program is presented by Dawn Rotellini (Chair, Development Grants Selection Committee) and

This 90-minute webinar on advocacy for National Member Organizations (NMOs) took place on October 27th, 2020. Dr. Alexsandro dos Santos Machado

Listen to this 1-hour webinar that took place on 3 September 2020 to learn stories of youth engagement around the